{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:08:39Z","timestamp":1790813319492,"version":"4.1.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Xihuang Pill\/Capsule is a traditional Chinese medicine used to treat cancers, such as breast and lung cancer. This study aimed to evaluate the safety of Xihuang Pill\/Capsule and its effect as an adjuvant treatment for lung cancer. A systematic literature search of the Wanfang, VIP, CNKI, Sinomed, PubMed, Embase, Web of Science, and MEDLINE Complete databases was performed to identify randomized controlled trials (RCTs) of Xihuang Pill\/Capsule for the adjuvant treatment of lung cancer. Data from the RCTs meeting the inclusion criteria were extracted, assessed for quality using the Cochrane Risk of Bias tool, and statistically analyzed using RevMan version 5.4 software. A total of 23 RCTs (1814 participants) were included. The primary outcomes revealed that Xihuang Pill\/Capsule combined with other therapies may increase the objective response rate (ORR; risk ratio [RR] =1.45, 95% confidence interval [CI] [1.33, 1.58],\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.00001) and disease control rate (DCR; RR = 1.18, 95% CI [1.12, 1.23],\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.00001), and subgroup analyses comparing the ORR and DCR of the different medication forms supported these findings. As secondary outcomes, tumor markers, Karnofsky Performance Status (KPS), T-cell subsets, and most adverse events improved after using Xihuang Pill\/Capsule. Based on existing clinical evidence, Xihuang Pill\/Capsule combined with conventional therapies improves tumor prognosis, patients\u2019 quality of life, and immune function in lung cancer and alleviates some adverse events associated with other antitumor therapies.\n                  <\/jats:p>","DOI":"10.4103\/jcrt.jcrt_2414_25","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:00:52Z","timestamp":1779951652000},"page":"447-457","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of Xihuang pill\/capsule as adjuvant therapy for lung cancer: A systematic review and meta-analysis"],"prefix":"10.4103","volume":"22","author":[{"given":"Yaping","family":"Guan","sequence":"first","affiliation":[{"name":"Department of First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"},{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjuan","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"},{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20260528","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"R2-20260528","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"key":"R3-20260528","first-page":"229","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R4-20260528","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-319-40389-2_2","article-title":"Diagnosis and molecular classification of lung cancer","volume":"170","author":"Rodriguez-Canales","year":"2016","journal-title":"Cancer Treat Res"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"100077","DOI":"10.1016\/j.engmed.2025.100077","article-title":"GA-AGN: A generative adversarial network and attention gated network model for enhanced lung cancer detection using chest CT scans","volume":"2","author":"Joseph","year":"2025","journal-title":"EngMedicine"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4103\/jcrt.jcrt_563_24","article-title":"Expert consensus on the multidisciplinary diagnosis and treatment of multiple ground glass nodule-like lung cancer (2024 Edition)","volume":"20","author":"Liu","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4103\/jcrt.jcrt_2244_25","article-title":"Surgery plus ablation (SPA): An emerging treatment modality for multiple ground glass nodule-like lung cancer","volume":"21","author":"Ye","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R8-20260528","doi-asserted-by":"crossref","first-page":"101946","DOI":"10.1016\/j.ctrv.2019.101946","article-title":"Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R9-20260528","doi-asserted-by":"crossref","first-page":"1541105","DOI":"10.3389\/fimmu.2025.1541105","article-title":"Interventional oncology and immunotherapy: Current status and future perspectives","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"R10-20260528","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"R11-20260528","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-025-01690-6","article-title":"Current and future therapies for small cell lung carcinoma","volume":"18","author":"Zhai","year":"2025","journal-title":"J Hematol Oncol"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.annonc.2025.09.018","article-title":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the phase III ALEX study","volume":"37","author":"Peters","year":"2026","journal-title":"Ann Oncol"},{"key":"R13-20260528","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"111381","DOI":"10.1016\/j.biopha.2021.111381","article-title":"Traditional Chinese medicine and lung cancer--From theory to practice","volume":"137","author":"Li","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"118955","DOI":"10.1016\/j.jep.2024.118955","article-title":"Traditional Chinese medicine enhances the effectiveness of immune checkpoint inhibitors in tumor treatment: A mechanism discussion","volume":"338","author":"Wang","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"R16-20260528","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/2159-8290.CD-24-0832","article-title":"Advancing cancer prevention through an AI-based integration of traditional and western medicine","volume":"14","author":"Zhang","year":"2024","journal-title":"Cancer Discov"},{"key":"R17-20260528","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-025-02245-6","article-title":"Traditional Chinese medicine in lung cancer treatment","volume":"24","author":"Xi","year":"2025","journal-title":"Mol Cancer"},{"key":"R18-20260528","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12943-024-02213-6","article-title":"Tailoring traditional Chinese medicine in cancer therapy","volume":"24","author":"Li","year":"2025","journal-title":"Mol Cancer"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"109570","DOI":"10.1016\/j.biopha.2019.109570","article-title":"Antitumor effects of immunity-enhancing traditional Chinese medicine","volume":"121","author":"Wang","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"116699","DOI":"10.1016\/j.jep.2023.116699","article-title":"Xihuang pill in the treatment of cancer: TCM theories, pharmacological activities, chemical compounds and clinical applications","volume":"316","author":"Xu","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"R22-20260528","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R23-20260528","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R25-20260528","first-page":"1307","article-title":"Clinical study of Xihuang Pill combined with Irinotecan and Cisplatn in the treatment of limited-stage small cell lung cancer [J]","volume":"33","author":"Cen","year":"2017","journal-title":"The Chinese Journal of Clinical Pharmacology"},{"key":"R26-20260528","first-page":"104","article-title":"Xihuang Pill combined with chemotherapy for the treatment of extensive-stage small cell lung cancer","volume":"13","author":"Chen","year":"2023","journal-title":"Journal of Frontiers of Medicine"},{"key":"R27-20260528","first-page":"102","article-title":"Efficacy and safety observation of Xihuang Pill combined with TP chemotherapy in the treatment of non-small cell lung cancer","volume":"51","author":"Chen","year":"2024","journal-title":"Liaoning Journal of Traditional Chinese Medicine"},{"key":"R28-20260528","first-page":"2235","article-title":"Application effect of Xihuang Capsule combined with Docetaxel plus Cisplatin second-line chemotherapy in patients with advanced non-small cell lung cancer","volume":"22","author":"Chen","year":"2024","journal-title":"Oncology Progress"},{"key":"R29-20260528","first-page":"12","article-title":"Clinical efficacy and safety of Xihuang Capsule combined with chemotherapy in the treatment of advanced lung adenocarcinoma","volume":"18","author":"Chen","year":"2020","journal-title":"Medical Diet and Health"},{"key":"R30-20260528","first-page":"34","article-title":"Clinical analysis of chemotherapy alone and combined with Xihuang Capsule in the treatment of advanced lung adenocarcinoma","volume":"37","author":"Du","year":"2018","journal-title":"J Anhui Univ Chin Med"},{"key":"R31-20260528","first-page":"12","article-title":"A prospective controlled study on the efficacy and safety of Xihuang Pill in the treatment of non-small cell lung cancer with heat syndrome\/heat-toxin syndrome","volume":"57","author":"Gao","year":"2019","journal-title":"Chin J Mod Dr"},{"key":"R32-20260528","first-page":"22","article-title":"Clinical observation on Xihuang Pill combined with chemotherapy in the treatment of mid-advanced stage non-small cell lung cancer","volume":"17","author":"Guo","year":"2008","journal-title":"J Emerg Tradit Chin Med"},{"key":"R33-20260528","first-page":"2384","article-title":"Observation on the clinical efficacy and toxic side effects of Xihuang Capsule combined with Gefitinib in the treatment of advanced lung adenocarcinoma","volume":"31","author":"He","year":"2018","journal-title":"J Med Theory Pract"},{"key":"R34-20260528","first-page":"305","article-title":"Observation on the efficacy of Vinorelbine +Cisplatin chemotherapy regimen combined with Xihuang Pill in the treatment of patients with lung squamous cell carcinoma","volume":"48","author":"He","year":"2020","journal-title":"Clin J Med Off"},{"key":"R35-20260528","first-page":"1","article-title":"Effects of Xihuang Capsule combined with chemotherapy on adverse reactions and immune function in patients with non-small cell lung cancer","volume":"3","author":"Liu","year":"2018","journal-title":"Syst Med"},{"key":"R36-20260528","first-page":"1214","article-title":"Effects of Xihuang Capsule combined with TP regimen on serum Foxp3 and Ang-2 levels in patients with advanced non-small cell lung cancer","volume":"17","author":"Liu","year":"2022","journal-title":"World J Integr Tradit West Med"},{"key":"R37-20260528","first-page":"113","article-title":"Randomized parallel controlled study of Xihuang Capsule combined with chemotherapy in treating lung cancer for reducing vascular endothelial growth factor","volume":"28","author":"Long","year":"2014","journal-title":"J Pract Tradit Chin Intern Med"},{"key":"R38-20260528","first-page":"111","article-title":"Effect of Xihuang Pill combined with PP chemotherapy regimen on patients with non-small cell lung cancer of phlegm-stasis mutual binding type","volume":"22","author":"Lu","year":"2025","journal-title":"Chin J Drug Appl Monit"},{"key":"R39-20260528","first-page":"1536","article-title":"Effects of Xihuang Capsule combined with albumin-bound paclitaxel as third-line or above therapy on advanced NSCLC: Efficacy and tumor markers","volume":"44","author":"Ma","year":"2023","journal-title":"Guangdong Med J"},{"key":"R40-20260528","first-page":"126","article-title":"Efficacy of Xihuang Capsule combined with Endostar and PC regimen in treating elderly patients with advanced driver gene-negative and PD-L1 expression-negative non-squamous non-small cell lung cancer","volume":"40","author":"Pei","year":"2025","journal-title":"Northwest Pharm J"},{"key":"R41-20260528","first-page":"60","article-title":"Clinical observation on 16 cases of advanced non-small cell lung cancer treated with Xihuang Pill combined with GP regimen","author":"Wang","year":"2009","journal-title":"Chinese Journal of Traditional Chinese Medicine, editors. Collection of Papers on Clinical Application Research of Xihuang Pill"},{"key":"R42-20260528","first-page":"36","article-title":"Observation on the efficacy of Xihuang Capsule combined with DP regimen in the treatment of middle-advanced non-small cell lung cancer","volume":"34","author":"Wang","year":"2024","journal-title":"J Microcirc"},{"key":"R43-20260528","first-page":"34","article-title":"Observation on the clinical efficacy of Xihuang Capsule in enhancing the effect of radiotherapy and chemotherapy for lung cancer","volume":"6","author":"Xiao","year":"2007","journal-title":"Tianjin Pharm"},{"key":"R44-20260528","first-page":"27","article-title":"Clinical efficacy and safety of Xihuang Pill combined with immunotherapy and EC chemotherapy as first-line treatment for extensive-stage small cell lung cancer","volume":"31","author":"Xiong","year":"2024","journal-title":"China Mod Med"},{"key":"R45-20260528","first-page":"111","article-title":"Efficacy analysis of Xihuang Capsule combined with DP regimen chemotherapy in the treatment of patients with middle-advanced non-small cell lung cancer","volume":"17","author":"Zhang","year":"2019","journal-title":"Chin Med Mod Distance Educ China"},{"key":"R46-20260528","first-page":"664","article-title":"Clinical observation on Xihuang Capsule in reducing toxic and side effects of chemotherapy for lung cancer","volume":"38","author":"Zhang","year":"2016","journal-title":"Guangxi Med J"},{"key":"R47-20260528","first-page":"174","article-title":"Application effect of Xihuang Capsule combined with gemcitabine plus cisplatin in patients with advanced lung squamous cell carcinoma","volume":"23","author":"Zhou","year":"2025","journal-title":"Oncol Prog"},{"key":"R48-20260528","doi-asserted-by":"crossref","first-page":"115357","DOI":"10.1016\/j.jep.2022.115357","article-title":"The efficacy and safety of Xihuang Pill\/capsule in adjuvant treatment of breast cancer: A systematic review and meta-analysis of 26 randomized controlled trials","volume":"295","author":"Ge","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"R49-20260528","doi-asserted-by":"crossref","first-page":"154491","DOI":"10.1016\/j.phymed.2022.154491","article-title":"Systems biology strategy and experimental validation to uncover the pharmacological mechanism of Xihuang Pill in treating non-small cell lung cancer","volume":"108","author":"Zhuang","year":"2023","journal-title":"Phytomedicine"},{"key":"R50-20260528","first-page":"259","article-title":"Research progress on active components and pharmacological effects of Xihuang Pill with predictive analysis of quality markers","volume":"30","author":"Wang","year":"2024","journal-title":"Chin J Exp Tradit Med Form"},{"key":"R51-20260528","doi-asserted-by":"crossref","first-page":"110533","DOI":"10.1016\/j.biopha.2020.110533","article-title":"Modulatory effects of Xihuang Pill on lung cancer treatment by an integrative approach","volume":"130","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R52-20260528","doi-asserted-by":"crossref","first-page":"e22516","DOI":"10.1097\/MD.0000000000022516","article-title":"Efficacy and safety of Xihuang pill for lung cancer: A protocol for systematic review and meta-analysis","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine (Baltimore)"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2414_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:39:20Z","timestamp":1787845160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2414_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2414_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}